AEterna Zentaris Inc. (AEZS)

[alexander77]

Strong cash position $33m as of March 31st, cash burn $2.8m/month. Two main products: (1) Zoptrex, phase 3 results available this quarter which could be the first FDA and EMA approved treatment for endometrial cancer
(2) Macrilen, phase 3 results available this quarter, to diagnose AGHD and AGHD after TBI. A much less invasive, less time consuming and less risky (no risk for hypoglycemic coma) compared to the insuline tolerance test. Two partnerships signed for Zoptrex for two of the most difficult-though very large and commercially very attractive - regions in the world: China + SouthEast Asia.
Two succesfully phase 2 results for Zoptrex for ovarian and prostate cancer, ready to go into phase 3.

Potential revenues for Zoptrex for endometrial cancer in the US alone: $300million/annually
Potential revenues for Macrilen (including AGHD caused by TBI) in the US alone: upto $200million/annually

US sales force already available b/c the company is already selling products for endocrinology, oncology and womens' health on a commission basis.

This is the most UNDERVALUED stock of the entire Nasdaq!